HRMY (Harmony Biosciences Holdings) Mohanram G-Score: 4 (As of Jun. 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
94 GF Score
Price $38.74
GF Value $46.93
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings Mohanram G-Score?

Harmony Biosciences Holdings HRMY +1.35% 94 Mohanram G-Score is 4 as of Jun. 2026, which is at its 10-year median of 4.00. GuruFocus rates HRMY with a GF Score™ of 94/100 and a GF Value™ of $46.93 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Harmony Biosciences Holdings has an G-score of 4.

The historical rank and industry rank for Harmony Biosciences Holdings's Mohanram G-Score or its related term are showing as below:

HRMY' s Mohanram G-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 4
Current: 4

During the past 8 years, the highest Piotroski G-score of Harmony Biosciences Holdings was 4. The lowest was 3. And the median was 4.

Harmony Biosciences Holdings  (NAS:HRMY) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Harmony Biosciences Holdings Mohanram G-Score Related Terms


Harmony Biosciences Holdings Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for Harmony Biosciences Holdings's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harmony Biosciences Holdings Mohanram G-Score Chart

Harmony Biosciences Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A 4.00

Harmony Biosciences Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 4.00 4.00 3.00 4.00

HRMY vs SION, URGN, PVLA: Mohanram G-Score Comparison

For the Biotechnology subindustry, Harmony Biosciences Holdings's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harmony Biosciences Holdings Mohanram G-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Mohanram G-Score falls into.


HRMY
94GF Score
Harmony Biosciences Holdings Inc HRMY
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harmony Biosciences Holdings Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Harmony Biosciences Holdings has an G-score of 4.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 4 mean?
Harmony Biosciences Holdings (HRMY) has a Mohanram G-Score of 4 as of Jun. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Harmony Biosciences Holdings and its competitors. This is near median its historical median of 4.00. Over the past decade, Harmony Biosciences Holdings' Mohanram G-Score has ranged from 3.00 to 4.00.
Is Harmony Biosciences Holdings' Mohanram G-Score too high?
Harmony Biosciences Holdings' current Mohanram G-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 4.00. Overall, Harmony Biosciences Holdings has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Mohanram G-Score compare to SION and URGN?
Harmony Biosciences Holdings' Mohanram G-Score of 4 can be compared against companies in the Biotechnology industry. Historically, Harmony Biosciences Holdings' own Mohanram G-Score has ranged from 3.00 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Biotechnology company?
A good Mohanram G-Score depends on the Biotechnology industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on Harmony Biosciences Holdings and its competitors. Harmony Biosciences Holdings's current Mohanram G-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.93, compared to a current price of $38.74 — trading 17.5% below its estimated fair value. The current Mohanram G-Score is 4, which is near median its 10-year median of 4.00. Harmony Biosciences Holdings' overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Mohanram G-Score is 4 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $38.74 is trading 17.5% below its estimated GF Value™ of $46.93. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • Mohanram G-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: $46.93 vs. price of $38.74 (17.5% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score

Get the complete analysis for HRMY

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.74
Price
$46.93
GF Value